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Transgenic Mice Overexpressing the 5-Hydroxytryptamine
Transporter Gene in Smooth Muscle Develop
Pulmonary Hypertension
Christophe Guignabert, Mohamed Izikki, Ly Ieng Tu, Zhenlin Li, Patricia Zadigue,
Anne-Marie Barlier-Mur, Naı¨ma Hanoun, David Rodman, Michel Hamon,
Serge Adnot, Saadia Eddahibi
Abstract—One intrinsic abnormality of pulmonary artery smooth muscle cells (PA-SMCs) in human idiopathic pulmonary
hypertension (iPH) is an exaggerated proliferative response to internalized serotonin (5-HT) caused by increased
expression of the 5-HT transporter (5-HTT). To investigate whether 5-HTT overexpression in PA-SMCs is sufficient
to produce PH, we generated transgenic mice overexpressing 5-HTT under the control of the SM22 promoter. Studies
in SM22-LacZ mice showed that the transgene was expressed predominantly in SMCs of pulmonary and systemic
vessels. Compared with wild-type mice, SM22–5-HTT mice exhibited a 3- to 4-fold increase in lung 5-HTT mRNA
and protein, together with increased lung 5-HT uptake activity, but no changes in platelet 5-HTT activity or blood 5-HT
levels. At 8 weeks of age, SM22–5-HTT mice exhibited PH, with marked increases in right ventricular systolic
pressure (RVSP), right ventricle/left ventricleseptum ratio, and muscularization of distal pulmonary vessels, but no
changes in systemic arterial pressure. PH worsened with age. Except a marked decrease in Kv channels, no changes in
the lung expression of mediators of pulmonary vascular remodeling were observed in SM22–5-HTT mice. Compared
with wild-type mice, SM22–5-HTT mice showed depressed hypoxic pulmonary vasoconstriction contrasting with
greater severity of hypoxia- or monocrotaline-induced PH. These results show that increased 5-HTT expression in
PA-SMCs, to a level close to that found in human iPH, lead to PH in mice. They further support a central role for 5-HTT
in the pathogenesis of PH, making 5-HTT a potential therapeutic target. (Circ Res. 2006;98:1323-1330.)
Key Words: serotonin transporter  pulmonary hypertension  vascular smooth muscle  transgenic mice
Pulmonary hypertension (PH) occurs as a complication ofvarious conditions or develops as a primary disease for
which no underlying cause can be found. Medial hypertrophy
and intimal thickening of pulmonary arteries are hallmark
pathological features that ultimately lead to vessel oblitera-
tion.1 Although hyperplasia of pulmonary-artery smooth mus-
cle cells (PA-SMCs) is considered the main component of
these changes, the nature of the primary defect responsible for
triggering and maintaining PA-SMC proliferation in PH is
poorly understood. In particular, to date, whether smooth
muscle hyperplasia results from an inherent characteristic of
PA-SMCs or from dysregulation of molecular events govern-
ing PA-SMC growth is still unknown.2,3
We recently reported that serotonin (5-hydroxytryptamine
[5-HT]) and its plasmic membrane transporter (5-HTT)
played a central role in the pathogenesis of PA-SMC prolif-
eration in experimental and human PH, whether idiopathic
(iPH) or associated with various diseases (aPH).4–6 A key
observation is that PA-SMCs from patients with iPH or aPH
proliferate excessively when they are exposed to 5-HT.6 In
contrast, these cells proliferate to the same extent as PA-
SMCs from control subjects when they are stimulated by
various growth factors such as PDGF, EGF, FGF, IGF, or
TGF-.5 This abnormal response to 5-HT is attributable to
overexpression of 5-HTT, which leads to increased internal-
ization of indoleamine, whose intracellularly mediated mito-
genic action is therefore enhanced.7,8 PA-SMCs from patients
with iPH maintain increased 5-HTT expression when cul-
tured, ie, removed from their in vivo environment, suggesting
that increased 5-HTT expression by these cells may be a
cardinal alteration in PH.5,6 However, it is not known whether
5-HTT overexpression occurring selectively in PA-SMCs is
sufficient to produce PH in vivo. This point is of particular
importance because 5-HTT expression is controlled by many
factors, including polymorphism of its gene promoter, hyp-
oxia, inflammatory cytokines, and drugs known to increase
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the risk of iPH in humans.5,8–10 Previous studies showed
greater severity of hypoxic PH in transgenic mice that
overexpress 5-HTT than in wild-type controls.11 However,
these transgenic animals also exhibit 5-HTT overexpression
in various cell types in addition to PA-SMCs, including
platelets, fibroblasts, endothelial cells, and neurons, which
may lead to major changes in central and peripheral 5-HT
bioavailibility. In a previous study of monocrotaline-induced
PH in rats, we found that increased 5-HTT expression
preceded the onset of PH, suggesting that 5-HTT overexpres-
sion occurred upstream to PH development in this model.9
However, many biological abnormalities are associated with
the onset of PH in monocrotaline-treated rats, which likely
interfered with the specific action of 5-HTT in the process of
pulmonary vascular remodeling.
In the present study, we generated mice that overexpressed
5-HTT under the control of the smooth muscle promoter
SM22 (SM22–5-HTT mice). The SM22 promoter was
chosen because it drives preferential expression of transgenes
in vascular smooth muscle (compared with visceral smooth
muscle) and in arteries (compared with veins).12 We ad-
dressed the following questions. (1) Do SM22–5-HTT mice
spontaneously develop PH in the absence of associated or
environmental stimuli? (2) Does PH induced by 5-HTT
overexpression occurring selectively in PA-SMCs share some
of the pathological and biological abnormalities encountered
in human PH? (3) Are SM22–5-HTT mice more susceptible
than paired wild-type mice to PH induced by various stimuli
including exposure to hypoxia or treatment with the active
monocrotaline derivative monocrotaline-pyrrole?
Materials and Methods
Production of SM22–5-HTT and SM22-LacZ
Transgenic Mice
Transgenic animals were produced as previously described.12 The
murine SM22 promoter (2191 bp starting 2126 bp before the start
site) was used to drive expression of the human 5-HTT gene or the
LacZ gene. All animal care and procedures were in accordance with
institutional guidelines.
Immunoblotting and Immunostaining
The tissues were sonicated in PBS containing anti-proteases, and 150
g of protein from each sample was used to detect 5-HTT protein as
previously described.4 The 5-HTT and -galactosidase proteins were
immunocytochemically labeled with polyclonal antibodies (Chemi-
con, Hampshire, UK) directed against 5-HTT and -galactosidase
(1:1000), respectively, as previously described.4
Lung and Platelet [3H]5-HT Uptake
Lung tissues were homogenized in the uptake buffer (120 mmol/L
NaCl, 5 mmol/L KCl, 1.2 mmol/L CaCl2, 1.2 mmol/L MgSO4,
5.6 mmol/L glucose, 4 mmol/L Tris-HCl, 6.25 mmol/L HEPES, and
0.5 mmol/L ascorbic acid, pH 7.4). Platelet and lung [3H]5-HT
uptake were measured with and without fluoxetine (105 mmol/L),
according to a previously described protocol.4
Blood 5-HT and 5-HIAA Concentrations
Serotonin and its metabolite 5-hydroxyindoleacetic acid (5-HIAA)
were assayed in whole blood using electrochemical detection by
high-performance liquid chromatography.13
Measurement of Systemic Arterial Pressure in
Normoxic Mice
To measure systemic arterial pressure, animals were anesthetized
with ketamine (60 mg/kg IP) and xylazine (10 mg/kg IP). The right
carotid was exposed, and a polyethylene catheter was inserted into
the carotid artery then connected to a pressure transducer.4
Assessment of PH
Mice were studied at 8, 20, and 55 weeks of age. Right ventricular
systolic pressure (RVSP) and heart rate were recorded and the Fulton
index (right ventricle/left ventricle plus septum [RV/LVS]) was
determined as previously described.4 The lungs were removed, fixed,
and processed for paraffin embedding. The percentage of muscular-
ized vessels was calculated as previously described.4 The cell
proliferation rate in muscularized vessels was estimated by
proliferating-cell nuclear antigen (PCNA) staining.9
Real-Time Quantitative PCR
Real-time quantitative PCR (RTQ-PCR) was used to measure lung
levels of mRNAs encoding 5-HTT, bone morphogenetic protein
receptor (BMPR)-II, BMPR-1A, BMPR-1B, BMP-2, BMP-4,
endothelin-1 (ET-1), Tie-2 receptor, prostacyclin (PGI2) synthase,
voltage-gated potassium channel (Kv)1.2, Kv1.5, Kv2.1, and Kv9.3,
as previously described.9
Effects of 5-HTT Activation on Kv Channel
Expression in Cultured Human PA-SMCs
The effects of 5-HT on Kv1.5 and Kv2.1 expression were studied on
cultured human PA-SMCs collected as previously described.5 Syn-
chronized cells were exposed to 5-HT (106 mol/L) with or without
fluoxetine (106 mol/L) in serum-free medium for 4 hours before
RNA extraction.
Figure 1. 5-HTT mRNA and protein in lung
tissues from transgenic SM22–5-HTT and
wild-type (WT) mice. A, Quantification of
products from RTQ-PCR obtained with prim-
ers recognizing both mouse and human
5-HTT mRNA. B, Western blot of 5-HTT pro-
tein in lungs from SM22–5-HTT and wild-
type mice. Relative protein levels were
assessed by densitometric quantification of
5-HTT immunoblotting normalized against the
-actin level. The antibodies recognized
human and mouse 5-HTT. Values are
meanSEM of 5 SM22–5-HTT and 6 wild-
type mice. *P0.01 compared with values
obtained in wild-type mice.
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Hemodynamic Response of Normoxic Mice to
Acute Hypoxia
Right ventricular systolic pressure and heart rate were performed
first while the animals were ventilated with room air then after 5
minutes of ventilation with a hypoxic gas mixture (8% O2, 92% N2).4
PH Induced by Exposure to Chronic Hypoxia or
by Treatment with Monocrotaline Pyrrole
Mice aged 8 weeks received a single IV injection of the active
monocrotaline derivative monocrotaline pyrrole (MCT-P) (5 mg/kg)
or were exposed to chronic hypoxia (10% O2, 90% N2). Preliminary
experiments revealed that intravenous administration of MCT-P
induced PH within 15 days. PH and vascular remodeling were
evaluated 2 weeks following hypoxia exposure or MCT-P injection.
Statistical Analyses
Data are presented as the meansSE. Statistical significance was
tested using the nonparametric Mann–Whitney test or 2-way
ANOVA followed by the Student–Newman–Keuls test.
Results
Validation of Transgene Function and
Tissue Distribution
Lung transgene expression by 8-week-old transgenic SM22–
5-HTT mice was measured using RTQ-PCR and Western
blot for 5-HTT mRNA and protein, respectively. SM22–5-
HTT mice showed a marked increase in lung 5-HTT
expression compared with wild-type controls, with 3- to
4-fold increases in 5-HTT mRNA and protein levels (Figure
1). Accordingly, lung [3H]5-HT uptake was 3 times higher in
SM22–5-HTT mice than in wild-type mice, whereas platelet
[3H]5-HT uptake did not differ between the 2 strains (Figure
2). To further validate the use of the SM22 promoter, we
generated SM22-lacZ mice. As shown in Figure 3A, SM22-
lacZ mice demonstrated -galactosidase immunostaining in
the media of pulmonary arteries but not in the bronchi. Most
of the pulmonary vessels were stained, indicating diffuse
transgene expression throughout the pulmonary vasculature.
Immunohistochemical studies were also performed to visual-
ize 5-HTT–like immunoreactivity in pulmonary vessels of
transgenic SM22–5-HTT and wild-type mice. As shown in
Figure 3B, 5-HTT immunostaining was detected in pulmo-
nary arteries from both SM22–5-HTT and wild-type mice
but with greater intensity in the transgenic mice.
Blood 5-HT and 5-HIAA Levels in Transgenic
SM22–5-HTT Mice and Wild-Type Mice
Whole-blood 5-HT levels did not significantly differ in
SM22–5-HTT mice and wild-type mice (21.01.5 and
20.81.6 mol/L, respectively; meansSEM, n6 in each
group). Similarly, blood 5-HIAA levels were similar in
Figure 2. Relative values of [3H]5-HT uptake by platelets (A) and
lung homogenates (B) from transgenic SM22–5-HTT and wild-
type (WT) mice. Nonspecific uptake was determined in the pres-
ence of the specific 5-HTT inhibitor fluoxetine (105 mol/L). Each
bar is the meanSEM of 6 independent determinations.
*P0.01 for comparison with values obtained in wild-type mice.
Figure 3. A, Immunohistochemical localization of
-galactosidase in lungs from transgenic SM22-
LacZ and wild-type mice. Paraffin sections of lung
tissues were used for immunohistochemical analy-
sis with anti–-galactosidase antibodies. Immuno-
reactivity was detected with 3,3-diaminobenzidine
(brown staining) and nuclei were counterstained
with hematoxylin (blue staining). Dense immuno-
staining is visible in the smooth muscle cells from
a pulmonary vessel of a transgenic SM22-LacZ
mouse, without staining in the bronchi. B, Immuno-
histochemical localization of 5-HTT in lungs from
transgenic SM22–5-HTT and wild-type mice.
5-HTT immunostaining is visible in the media of
pulmonary vessels and appears stronger in the
medial layer of remodeled pulmonary arteries from
SM22–5-HTT mice. Scale bar50 m.
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transgenic (0.6120.040 mol/L, n5) and wild-type
(0.7160.048 mol/L, n5) mice.
Development of PH and Vascular Remodeling in
SM22–5-HTT Mice
SM22–5-HTT mice (8-weeks old) did not differ from
wild-type mice with respect to body weight (231 g versus
222 g, PNS), systemic arterial pressure (935 mm Hg
versus 913 mm Hg, PNS), or heart rate (36014 bpm
versus 34211 bpm, n6 in each group, PNS). In contrast,
RVSP and RV/LVS weight ratio were significantly higher
in SM22–5-HTT mice than in wild-type controls, indicating
the presence of sustained PH in transgenic mice (Figure 4).
SM22–5-HTT mice experienced PH progression over time,
with higher RVSP values at 55 weeks than at 20 weeks and
at 20 weeks than at 8 weeks (Figure 4A). Concomitantly,
SM22–5-HTT mice developed marked pulmonary vascular
remodeling, as shown by increased density of muscularized
pulmonary vessels in SM22–5-HTT mice at any age com-
pared with wild-type mice (Figure 4C). As illustrated in
Figure 4, muscularization was more prominent in 20-week-
old mice than in 8-week-old mice and was greatest in
55-week-old mice. In SM22–5-HTT mice, PCNA labeling
showed proliferation of smooth muscle cells in distal pulmo-
nary vessel walls (Figure 4D). PCNA-positive cell counts
were 606% and 5512% in muscularized pulmonary ves-
sels from SM22–5-HTT mice aged 20 and 55 weeks,
respectively, compared with 62% in vessels from wild-type
mice (P0.01).
Lung Molecular Alterations Induced by 5-HTT
Overexpression in SM22–5-HTT Mice
We investigated whether development of PH in SM22–5-
HTT mice was associated with changes in the expression of
genes involved in pulmonary vascular remodeling. Using
RTQ-PCR, we found that lung levels of mRNAs encoding
ET-1, Tie2 receptor, prostacyclin-synthase, BMPR-2,
BMPR-1A, BMPR-1B, BMP-2, BMP-4, Kv1.2, and Kv9.3
were not altered in SM22–5-HTT mice compared with
wild-type controls (Figure 5). In contrast, both Kv1.5 and
Kv2.1 mRNA levels were markedly decreased in lungs from
SM22–5-HTT mice compared with controls at 20 weeks of
age (Figure 5C). Because Kv1.5 and Kv2.1 channels are
predominantly expressed by SMCs,14 we performed addi-
tional in vitro studies on human PA-SMCs to examine the
effect of 5-HT on the expression of these channels. As shown
in Figure 6, incubation of PA-SMCs with 5-HT (106 mol/L)
for 4 hours dramatically reduced Kv1.5 mRNA levels. This
effect was abolished by the selective 5-HTT inhibitor fluox-
etine (106 mol/L).
Hemodynamic Responses to Acute Hypoxia
The effect of an acute hypoxic challenge on RVSP was
examined in 20-week-old normoxic mice (Figure 7). Expo-
sure to 8% O2 elicited a marked increase in RVSP in
wild-type mice (from 18.20.6 to 23.10.7 mm Hg;
P0.01) but not in SM22–5-HTT mice (from 28.10.7 to
28.60.6 mm Hg). Heart rates were similar in transgenic and
wild-type mice.
Figure 4. Development of PH and vascular remodeling in SM22–5-HTT vs wild-type mice at 8 and 20 weeks of age under normoxic
conditions. A, RV systolic pressure. B, Fulton index: RV/LVS. C, Percentage of muscularized vessels. D, In situ PA-SMC proliferation
in muscularized vessels of SM22–5-HTT and wild-type (WT) mice at 20 weeks of age, shown by immunohistochemistry for PCNA. To
quantify VSMC proliferation, we counted PCNA-positive cells in the media of muscularized vessels and expressed the result as the per-
centage of the total smooth muscle cell count. Representative pictures of PCNA staining. Scale bar50 m. Values are meansSEM
(n10 in each group). *P0.05 and **P0.01 compared with values in wild-type mice; §P0.05 compared with corresponding values
in 8-week-old mice; #P0.05 compared with corresponding values in 20-week-old mice (A and C).
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PH in SM22–5-HTT and Wild-Type Mice After
Exposure to Chronic Hypoxia or Treatment With
Monocrotaline-Pyrrole
These experiments were performed to investigate whether PH
induced by chronic hypoxia or MCT-P was more severe in
SM22–5-HTT mice than in wild-type mice. Mice aged 8
weeks were used for these studies. Fifteen days after exposure
to 10% O2 or treatment with MCT-P, both SM22–5-HTT
and wild-type mice exhibited increases in RVSP (Figure 8A),
Fulton index (Figure 8B), and muscularization of pulmonary
vessels (Figure 8C) compared with preexposure values.
However, the RVSP increase and degree of RV hypertrophy
and distal pulmonary vessel muscularization were more severe
in SM22–5-HTT mice than in wild-type mice following ad-
ministration of MCT-P or exposure to hypoxia (Figure 8).
Discussion
Our results show that transgenic mice with 5-HTT overex-
pression occurring selectively in SMCs spontaneously de-
velop PH. Because 5-HTT overexpression in PA-SMCs is a
characteristic of human iPH or aPH, these data indicate that
5-HT internalization by PA-SMCs plays a prominent role in
the pathogenesis of human PH. One major point is that PH in
SM22–5-HTT mice developed despite unaltered 5-HT bio-
availibility, solely as a consequence of increased 5-HTT
protein expression in SMCs. We found that genes belonging
to the BMP pathway and genes expressed by endothelial
cells, whose expression is usually altered in human or
experimental PH, remained unaltered in the lungs of SM22–
5-HTT mice. In contrast, the expression of Kv channels
which are predominantly expressed by PA-SMCs, was lower
in SM22–5-HTT mice than in wild-type mice. Compared
with wild-type mice, SM22–5-HTT mice showed depressed
hypoxic pulmonary vasoconstriction but developed more
severe hypoxia- or monocrotaline-induced PH.
The main question addressed in this study was whether
induction in mice of an intrinsic abnormality constantly found
in PA-SMCs from patients with various forms of PH was
sufficient to induce PH in the absence of other stimuli. The
use of the SM22 promoter to drive 5-HTT expression
Figure 5. Relative lung levels of mRNAs encoding BMPR2, BMPR1A, BMPR1B, BMP-2, BMP-4 (A); endothelin (ET-1), Tie-2 receptor,
and prostacyclin (PGI2) synthase (B); and voltage-dependent potassium channels Kv1.2, Kv1.5, Kv2.1, and Kv9.3 (C) in wild-type (WT)
and SM22–5-HTT mice at 20 weeks of age under normoxic conditions. Values are meansSEM. *P0.05 and **P0.01 compared
with respective values in wild-type mice.
Figure 6. Effects of 5-HT (106 mol/L) on Kv1.5
and Kv2.1 mRNA levels in cultured human pulmo-
nary artery smooth muscle cells. The response to
5-HT was also measured in the presence of 105
mol/L fluoxetine. Values are meansSEM of 6
independent experiments. *P0.01 compared with
control values in nonstimulated, basal condition.
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selectively in SMCs caused a 3- to 4-fold increase in lung
5-HTT protein levels. SM22–5-HTT mice studied at 8
weeks of age developed PH, as reflected by significant
increases in RVSP, Fulton index, and muscularization of
distal pulmonary vessels. Increased PA-SMC proliferation
appeared to be the main factor in pulmonary vascular remod-
eling in SM22–5-HTT mice, as reflected by the increased
PCNA labeling of pulmonary vessels. PH worsened with age,
as a result of progressive pulmonary vessel remodeling. The
level of increased 5-HTT expression in SM22–5-HTT mice
was very close to that found in humans with PH. 5-HTT
expression in PA-SMCs from patients with iPH or aPH is
usually 2- to 4-fold that of control subjects, depending on the
type of PH and on the individual genotype.5,6 The fact that
SM22–5-HTT mice spontaneously developed PH therefore
indicates that vascular 5-HTT overexpression per se is suffi-
cient to induce PA-SMC hyperplasia and subsequent devel-
opment of PH.
The 5-HTT protein is known to be responsible for the
internalization and storage of 5-HT in platelets and neurons.
Consequently, changes in 5-HTT expression might be ex-
pected to induce major changes in circulating 5-HT levels
and/or 5-HT bioavailability in the central nervous system and
in peripheral tissues. Although in previous studies, transgenic
mice with 5-HTT overexpression driven by the human 5-HTT
gene promoter were more susceptible to hypoxic PH than
wild-type mice, these transgenic mice probably had addi-
tional alterations in 5-HT bioavailibility.11 In our study, these
alterations were limited by the use of a promoter that was
selective for SMCs. As a consequence, neither platelet 5-HT
uptake nor blood levels of 5-HT or its metabolite 5-HIAA
differed significantly between transgenic and wild-type mice.
Thus, another striking finding from our study is that 5-HTT
protein overexpression in SMCs led to pulmonary vascular
remodeling and PH despite the absence of associated changes
in indoleamine bioavailability.
It is noteworthy that in SM22-LacZ mice the SM22
promoter was found to direct lung -galactosidase expression
chiefly in the media of pulmonary arteries, inducing only
faint -galactosidase immunostaining in bronchial SMCs.
This observation is consistent with previous studies showing
that the SM22 promoter drives preferential expression of
transgenes in vascular smooth muscle, as opposed to visceral
smooth muscle.12 In SM22–5-HTT mice, the 5-HTT expres-
sion increase occurred in the media of all types of vessels,
including pulmonary and systemic arteries. However, vascu-
lar remodeling developed only in the pulmonary circulation
of the transgenic mice, which exhibited no structural changes
in the carotid arteries or differences in blood pressure
compared with wild-type mice. The differential effects of
5-HTT overexpression in pulmonary versus systemic vessels
are consistent with our previous findings that the mitogenic
effect of 5-HT on SMCs is mediated by 5-HTT only in
PA-SMCs.8 These findings are of clinical relevance because
they suggest that conditions associated with increased 5-HTT
expression in a given individual might predominantly affect
pulmonary vessels. SM22 is expressed in the embryonic
pulmonary vasculature, raising the possibility that pulmonary
vascular remodeling may have developed in SM22–5-HTT
as a result of a congenital defect in the pulmonary vascula-
ture. However, examination of pulmonary vessels from neo-
Figure 7. Individual and mean (horizontal line) RSVP in normoxic
wild-type and SM22–5-HTT mice while ventilated with room air
(normoxia) and after 5 minutes of ventilation with a hypoxic gas
mixture (hypoxia). Baseline RVSP during normoxic ventilation
was higher in SM22–5-HTT than in wild-type mice. RSVP
increased in wild-type mice but not SM22–5-HTT mice.
*P0.01 for comparison with values recorded during normoxia.
Figure 8. Development of PH in SM22–5-HTT and wild-type mice exposed to chronic hypoxia or treated with the active monocrotaline
derivative monocrotaline-pyrrole (MCT-P). RV systolic pressure (A), Fulton index (RV/LVS) (B), and percentage of muscularized pulmo-
nary vessels (C) in SM22–5-HTT and wild-type mice at 8 weeks of age after a 2-week exposure to 10% O2 or after treatment with
MCT-P (5 mg/kg IV). Values are meansSEM (n10 in each group). *P0.05 and **P0.01 compared with corresponding values in
wild-type mice; §P0.05 and §§P0.01 compared with corresponding values in normoxic mice.
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natal animals failed to show marked differences between
SM22–5-HTT and wild-type mice.
Investigating SM22–5-HTT mice has shed light on rela-
tionships between molecular pathways known to affect pul-
monary vascular remodeling. First, BMPRII has been identi-
fied as the gene causing familial PH, and BMPRII/ mice
were recently shown to be more susceptible than control mice
to PH induced by inflammatory stimuli.15–17 BMPRII/
mice, however, do not develop PH spontaneously.17 We
investigated the BMP pathways in SM22–5-HTT mice by
measuring lung expression of BMPRII, BMPRIa, BMPRIb,
BMP-2, and BMP-4. No alterations in lung levels of mRNAs
encoding these molecules were found, suggesting that the
BMPRII pathway was not involved in PH in SM22–5-HTT
mice. Second, we investigated whether endothelial cell alter-
ations might have contributed to PH in SM22–5-HTT mice.
A consistent feature of various types of experimental or
human PH is increased lung expression of ET-1, which may
be associated with downregulation of prostacyclin synthase
and activation of Tie2 receptors.18–21 In lungs from SM22–
5-HTT mice, expression of ET-1, Tie2 receptor, and pros-
tacyclin synthase was not significantly different from that in
wild-type animals, suggesting that PH in these transgenic
mice developed without a major contribution from endothe-
lial cells. Third, key actors of the contractile and proliferative
status of PA-SMCs are voltage-gated K channels (Kv) in-
cluding Kv1.2, Kv1.5, Kv2.1, and Kv9.3.14 It is now well
established that blockade or downregulation of Kv channels,
notably Kv1.5 and Kv2.1, causes membrane depolarization
and stimulates PA-SMC proliferation.22,23 Inhibition of 1 or
several of these channels by acute hypoxia also contributes to
initiate hypoxic pulmonary vasoconstriction.22,24 Because
reduced expression of these channels is a characteristic
feature of human idiopathic PH and of hypoxia-induced
PH,22,25,26 1 current hypothesis is that downregulation of Kv
channels contributes importantly to the pathogenesis of var-
ious types of experimental and human PH. In our study, lung
expression of both Kv1.5 and Kv2.1 channels was markedly
decreased in SM22–5-HTT mice. Interestingly, treatment of
human PA-SMCs by 5-HT in vitro induced a similar marked
reduction in the expression of Kv1.5 channels, indicating that
downregulation of this channel was not related to the remod-
eling process per se, but rather appeared to be a downstream
effect of 5-HT internalization by these cells. Therefore, a
direct link between 5-HTT and Kv channels might explain
why these membrane-bound proteins show opposite varia-
tions in PH of various origins. The molecular link between
5-HTT and Kv channels remains to be identified, although
downstream effects of 5-HTT activation may involve
NADPH oxidase activity,27 which has been shown to alter Kv
channel expression and/or activity.28,29 One may suggest that
some of the cellular effects of 5-HTT overexpression in
SM22–5-HTT mice were mediated by downregulation of Kv
channels. Although such a hypothesis is beyond the scope of
our study, some of the functional abnormalities in SM22–5-
HTT mice were probably related to changes in Kv channels.
Indeed, it is now well established that 1 direct consequence of
Kv channel downregulation is a reduction in the extent of
hypoxic pulmonary vasoconstriction.22 Interestingly, in
SM22–5-HTT mice, the pulmonary pressure response to
hypoxia was completely abrogated, indicating that these mice
are unresponsive to acute hypoxic vasoconstriction. These
results are consistent with those obtained during chronic
hypoxia, where increased PA-SMC proliferation coexists
with blunted hypoxic vasoconstriction because PA-SMCs are
in a depolarized state. Moreover, these results agree with our
previous finding that hypoxic pulmonary vasoconstriction in
5-HTT knock-out mice was, on the contrary, potentiated.4
Although SM22–5-HTT mice did not develop hypoxic
pulmonary vasoconstriction, they experienced PH of greater
severity compared with wild-type controls after exposure to
chronic hypoxia or the monocrotaline pyrrole derivative. In
previous studies in both rats and mice, we found that these 2
types of PH were associated with 5-HTT overexpression and
that deleting the 5-HTT gene or pharmacologically inhibiting
5-HTT activity protected against hypoxia- or monocrotaline-
induced PH.4,9 5-HTT mice did not appear more sensitive to
chronic hypoxia or to monocrotaline than wild-type mice,
indicating that 5-HTT overexpression did not act synergisti-
cally with hypoxia or monocrotaline to cause PH. These
results are consistent with the fact that 5-HTT transgene
expression, in contrast to the 5-HTT gene, is unresponsive to
external stimuli such as those induced by hypoxia or mono-
crotaline.8,9 Our results are, therefore, consistent with the
proposal that the level of 5-HTT expression is an important
modifier of the PH phenotype, whatever the cause of PH. In
line with this conclusion, we recently provided evidence that
the severity of PH in patients with chronic obstructive lung
disease is closely related to polymorphism of the 5-HTT gene
promoter.30 In particular, PH was particularly severe in
patients who carried the biallelic L form of the 5-HTT gene
promoter. Polymorphism of the 5-HTT gene promoter, how-
ever, cannot explain the high expression of 5-HTT in PA-
SMCs from patients with either iPH or aPH. Whether
increased 5-HTT expression occurs as a primary defect or is
secondary to other abnormalities in human PH remains an
unsolved question. In any case, our results in mice demon-
strate clearly that 5-HTT overexpression is a key factor
during PH development. SM22–5-HTT mice should now be
considered a useful in vivo model for investigating how
environmental and/or genetic factors modify their PH
phenotype.
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